000			02358 a2200637 4500
005			20250514221023.0
264		0	_c20050713
008			200507s 0 0 eng d
022			_a0006-4971
024	7		_a10.1182/blood-2004-08-3035 _2doi
040			_aNLM _beng _cNLM
100	1		_aMcLaughlin, Peter
245	0	0	_aMyelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. _h[electronic resource]
260			_bBlood _cJun 2005
300			_a4573-5 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Murine-Derived
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aChromosome Aberrations
650	0	4	_aChromosomes, Human, Pair 7
650	0	4	_aCombined Modality Therapy
650	0	4	_aDNA Damage
650	0	4	_aDexamethasone _xadministration & dosage
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aImmunotherapy _xmethods
650	0	4	_aInterferon-alpha _xadministration & dosage
650	0	4	_aLeukemia, Myeloid, Acute _xchemically induced
650	0	4	_aLymphoma _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMitoxantrone _xadministration & dosage
650	0	4	_aMonosomy
650	0	4	_aMyelodysplastic Syndromes _xchemically induced
650	0	4	_aRemission Induction
650	0	4	_aRituximab
650	0	4	_aTime Factors
650	0	4	_aVidarabine _xadministration & dosage
700	1		_aEstey, Elihu
700	1		_aGlassman, Armand
700	1		_aRomaguera, Jorge
700	1		_aSamaniego, Felipe
700	1		_aAyala, Ana
700	1		_aHayes, Kimberly
700	1		_aMaddox, Anne Marie
700	1		_aPreti, H Alejandro
700	1		_aHagemeister, Fredrick B
773	0		_tBlood _gvol. 105 _gno. 12 _gp. 4573-5
856	4	0	_uhttps://doi.org/10.1182/blood-2004-08-3035 _zAvailable from publisher's website
999			_c15415303 _d15415303